TÜBINGEN, GERMANY and HOUSTON, TX / ACCESSWIRE / April 16, 2024 / CureVac N.V. (Nasdaq:CVAC) ('CureVac'), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ('mRNA'), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines..

德国TÜBINGEN和德克萨斯州休斯顿/ACCESSWIRE/2024年4月16日/CureVac N.V.（纳斯达克：CVAC）（“CureVac”），一家全球生物制药公司，开发了一类基于信使核糖核酸（“mRNA”）的新型转化药物，德克萨斯大学MD安德森癌症中心今天宣布了一项共同开发和许可协议，以开发新型基于mRNA的癌症疫苗。。

The collaboration creates strong synergies between CureVac's unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson's expertise in cancer antigen discovery and validation, translational drug development, and clinical research. The collaboration will focus on the development of differentiated cancer vaccine candidates in selected hematological and solid tumor indications with high unmet medical need..

该合作在CureVac独特的癌症抗原发现，mRNA设计和制造端到端能力与MD Anderson在癌症抗原发现和验证，转化药物开发和临床研究方面的专业知识之间产生了强大的协同作用。该合作将侧重于在选定的血液学和实体瘤适应症中开发未满足医疗需求的分化型癌症候选疫苗。。

'We look forward to collaborating with the team at MD Anderson to push the boundaries of mRNA technology and develop impactful therapeutic options for patients in need,' said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. 'In combining our respective expertise, we believe we can go further and faster to develop novel, off-the-shelf, mRNA-based cancer vaccines that have the potential to significantly improve patient outcomes.'.

CureVac首席执行官亚历山大·森德（AlexanderZehnder）博士说：“我们期待着与MD Anderson的团队合作，推动mRNA技术的发展，为有需要的患者开发有效的治疗选择。”结合我们各自的专业知识，我们相信我们可以进一步更快地开发新的，现成的，基于mRNA的癌症疫苗，这些疫苗有可能显着改善患者的预后。”。

Both parties will contribute to the identification of differentiated cancer antigens based on whole genome sequencing, combined with long- and short-read RNA sequencing and cutting-edge bioinformatics. Joint preclinical validation of the highest-quality cancer antigens will be supported by Sachet Shukla, Ph.D., Assistant Professor of Hematopoietic Biology & Malignancy and director of the department's cancer vaccine program, and by MD Anderson's ECLIPSE (Evolution of Cancer, Leukemia, and Immunity Post Stem cEll transplant) platform, part of the institution's Therapeutics Discovery division..

双方将基于全基因组测序，结合长读和短读RNA测序和尖端生物信息学，为鉴定分化的癌症抗原做出贡献。最高质量癌症抗原的联合临床前验证将得到造血生物学与恶性肿瘤助理教授兼该部门癌症疫苗计划主任Sachet Shukla博士以及MD Anderson的ECLIPSE（癌症，白血病和干细胞移植后免疫的进化）平台的支持，该平台是该机构治疗发现部门的一部分。。

'We are excited for cancer vaccines to potentially emerge as an essential therapeutic tool in the future,' Shukla said. 'This collaboration with CureVac is an important milestone in our efforts and brings together complementary strengths toward our goal of developing transformative vaccines for cancer.'.

舒克拉说：“我们很高兴癌症疫苗将来可能成为一种重要的治疗工具。”与CureVac的合作是我们努力的一个重要里程碑，并为我们开发癌症转化疫苗的目标汇集了互补优势。”。

Following selection of the most promising validated vaccine candidates and completion of Investigational New Drug (IND) approvals, MD Anderson will be responsible for conducting initial Phase 1/2 studies in appropriate clinical indications.

在选择最有希望的经过验证的候选疫苗并完成研究性新药（IND）批准后，MD Anderson将负责在适当的临床适应症中进行初始1/2期研究。

'Our ECLIPSE team uses proprietary high-throughput technology to identify and validate immune targets, and we are driven to advance impactful immunotherapies with the potential to transform the lives of patients with cancer,' said Jeffrey Molldrem, M.D., chair of Hematopoietic Biology and Malignancy and leader of the ECLIPSE platform at MD Anderson.

“我们的ECLIPSE团队使用专有的高通量技术来识别和验证免疫靶标，我们致力于推进有影响力的免疫疗法，并有可能改变癌症患者的生活，”MD Anderson的造血生物学和恶性肿瘤主席兼ECLIPSE平台负责人Jeffrey Moldrem医学博士说。

'Together with CureVac, we hope to embrace this exciting area of drug discovery and development in pursuit of mRNA vaccines that will address significant unmet medical need.'.

“与CureVac一起，我们希望拥抱这一令人兴奋的药物发现和开发领域，以寻求能够解决重大未满足医疗需求的mRNA疫苗。”。

Under the terms of the collaboration agreement, CureVac and MD Anderson will jointly contribute to and support development of those programs designated to move forward. CureVac has worldwide exclusive rights to late-stage development, commercialization, or partnering of the cancer vaccine candidates.

根据合作协议的条款，CureVac和MD Anderson将共同促进和支持这些计划的发展。CureVac拥有癌症疫苗候选物的后期开发，商业化或合作的全球独家权利。

MD Anderson is eligible for certain downstream payments based on potential future commercialization..

MD Anderson有资格根据未来潜在的商业化获得某些下游付款。。

About CureVac

关于CureVac

CureVac (Nasdaq:CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.

CureVac（纳斯达克股票代码：CVAC）是信使RNA（mRNA）技术领域的全球生物制药公司，在开发，优化和制造这种用于医疗目的的多功能生物分子方面拥有20多年的专业知识。CureVac专有技术的原理是使用优化的mRNA作为数据载体，指导人体产生能够抵抗多种疾病的自身蛋白质。

In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac's second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies.

2020年7月，CureVac与GSK合作，共同开发基于CureVac第二代mRNA技术的传染病预防性疫苗新产品。这种合作后来扩展到开发第二代COVID-19候选疫苗和改进的mRNA疫苗技术。

Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland, and the U.S.

基于其专有技术，CureVac在预防性疫苗、癌症治疗、抗体治疗和罕见疾病治疗领域建立了一条深入的临床管道。CureVac N.V.的总部位于德国蒂宾根，在德国、荷兰、比利时、瑞士和美国的工厂拥有1100多名员工。

About MD Anderson

关于MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution's sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation's first National Cancer Institute (NCI)-designated comprehensive cancer centers.

位于休斯顿的德克萨斯大学MD安德森癌症中心是世界上最受尊敬的癌症患者护理、研究、教育和预防中心之一。该机构的唯一使命是为世界各地的患者及其家人终止癌症，并于1971年成为美国第一家国家癌症研究所（NCI）指定的综合癌症中心之一。